Background Alzheimer's disease is the most common cause of dementia in older people.
One approach to symptomatic treatment of Alzheimer's disease is to enhance cholinergic …

Cerebral hypoperfusion due to impaired bioavailability of nitric oxide (NO) synthesized by
endothelial nitric oxide synthase and neuronal nitric oxide synthase leads to cognitive …

Alzheimer's disease (AD) is a progressive, neurodegenerative disease characterized by an
increasing incidence. One of the pathologic processes that underlie this disorder is …

Background: Cerebral microangiopathy in Alzheimer's disease (AD) causes chronic
hypoperfusion and probably accelerates neurodegenerative changes. Objective: We …

There has been a growing interest in vascular impairment associated with Alzheimer's
disease (AD). This interest was stimulated by the findings of higher incidence of vascular risk …

Cerebral vascular resistance and blood flow were widely considered to be regulated solely
by tonic innervation of vasoconstrictor adrenergic nerves. However, pieces of evidence …

This rapid review and network meta-analysis was conducted to update an existing review of
the safety and efficacy of cognitive enhancers for patients with Alzheimer's Disease. A …

Background: Vascular dementia is one of the most common forms of dementia. At now, there
is no treatment available to cure vascular dementia or to alter its clinical course. Some …

抄録 アルツハイマー病 (AD) の治療にドネペジルを始めとするアセチルコリンエステラーゼ (AChE)
阻害薬が広く使用されている. これらの薬物は, AD 患者の脳組織で減弱しているコリン作動性神経 …